Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

This study is testing a combination of two drugs — anlotinib (a drug that cuts off blood supply to tumors) and an immune checkpoint inhibitor (a drug that helps your immune system fight cancer) — for people with lung cancer whose disease progressed after first-line treatment combining chemotherapy and immunotherapy. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with lung cancer confirmed by biopsy - Your cancer has stopped responding to a previous treatment that combined chemotherapy and immunotherapy - You are in reasonably good physical condition (ECOG 0–1) - You have a life expectancy of at least 12 weeks - You have stable brain metastases (if any) - Your blood counts and organ function are adequate **You may NOT be eligible if...** - You have cancer that has spread to the fluid around the spinal cord or causing spinal cord compression - You have had another cancer in the last 2 years - You have significant side effects left over from prior treatment - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.